Dr. Purvi K. Mehra

Internal Medicine
Artemis Medical Group Inc.
770 Washington St Ste 200, 
San Diego, CA 
Artemis Medical Group Inc.
770 Washington St Ste 200, 
San Diego, CA 

Overview

Purvi Mehra is a primary care provider, practicing in Internal Medicine in San Diego, California.

Her clinical expertise encompasses Maturity Onset Diabetes of the Young, Osteoarthritis, Methicillin-Resistant Staphylococcus Aureus (MRSA), and Arthritis.

She is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 10 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO

Locations

Artemis Medical Group Inc.
770 Washington St Ste 200, San Diego, CA 92103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Enrollment Status: Completed
Publish Date: May 22, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Chronic Low Back Pain
Enrollment Status: Completed
Publish Date: November 30, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Diabetic Peripheral Neuropathic Pain
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: LY3016859
Study Phase: Phase 2
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Osteoarthritis Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Osteoarthritis Pain
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drug: LY3556050
Study Phase: Phase 2
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Semaglutide
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: June 12, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: August 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

11 Total Publications

A Randomized, Open-Label, Single-Dose Study to Assess Safety and Systemic Exposure of Triamcinolone Acetonide Extended-Release in Patients With Hip Osteoarthritis.
A Randomized, Open-Label, Single-Dose Study to Assess Safety and Systemic Exposure of Triamcinolone Acetonide Extended-Release in Patients With Hip Osteoarthritis.
Journal: Rheumatology and therapy
Published: November 12, 2021
Similar Doctors
Expertise in
13
conditions
Dr. Bruce L. Zuraw
Internal Medicine
Expertise in
13
conditions
Dr. Bruce L. Zuraw
Internal Medicine

UC San Diego

200 W Arbor Dr, 
San Diego,, CA 
 (0.5 miles away)
858-657-8322
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bruce Zuraw is a primary care provider, practicing in Internal Medicine in San Diego,, California. Dr. Zuraw is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Angioedema, Hereditary Angioedema, Hives, Asthma, and Hormone Replacement Therapy (HRT).

Expertise in
19
conditions
Dr. Arthur F. Kavanaugh
Internal Medicine
Expertise in
19
conditions
Dr. Arthur F. Kavanaugh
Internal Medicine
Before you request

UC San Diego Health Clinical Laboratory-La Jolla

9350 Campus Point Dr, 
La Jolla, CA 
 (9.6 miles away)
800-926-8273
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arthur Kavanaugh is a primary care provider, practicing in Internal Medicine in La Jolla, California. Dr. Kavanaugh is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Psoriatic Arthritis, Arthritis, Psoriasis, and Necrosis. Dr. Kavanaugh is currently accepting new patients.

Expertise in
13
conditions
Dr. Fouad J. Moawad
Internal Medicine
Expertise in
13
conditions
Dr. Fouad J. Moawad
Internal Medicine

Scripps Clinic John R. Anderson V Medical Pavilion

9898 Genesee Ave, 
La Jolla, CA 
 (10.1 miles away)
858-824-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Fouad Moawad is a primary care provider, practicing in Internal Medicine in La Jolla, California. Dr. Moawad is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Esophagitis, Eosinophilic Esophagitis, Gastroesophageal Reflux Disease (GERD), Endoscopy, and Colonoscopy.

Frequently Asked Questions about Dr. Purvi K. Mehra

How do I make an appointment with Dr. Purvi K. Mehra?

You can book an appointment with Dr. Purvi K. Mehra by calling their office at 858-278-3647. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Purvi K. Mehra a top-rated expert for Maturity Onset Diabetes of the Young?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Purvi K. Mehra is classified as an Experienced expert for Maturity Onset Diabetes of the Young, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Purvi K. Mehra specialize in?

While Dr. Purvi K. Mehra is a Internal Medicine, they have specific expertise in Maturity Onset Diabetes of the Young, Osteoarthritis, and Methicillin-Resistant Staphylococcus Aureus (MRSA). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Purvi K. Mehra participate in research or clinical trials?

Yes. Dr. Purvi K. Mehra has published 11 articles and abstracts on conditions like Maturity Onset Diabetes of the Young. You can view a list of Dr. Purvi K. Mehra's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Purvi K. Mehra accept my insurance?

Dr. Purvi K. Mehra accepts most major insurance plans, including Aetna and Blue Shield of California. We recommend calling the office directly at 858-278-3647 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mehra's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile